disease, except for insulin resistance and oxidative stress, are still unknown because suitable animal models have not been established.
SHRSP5/Dmcr is a newly established substrain of strokeprone (SP) spontaneously hypertensive rat. SHRSP5/Dmcr rats fed the high-fat and high-cholesterol (HFC) diets were first reported in 2012 as a novel rat model for the development of hepatic lesions similar to those of human NASH pathology. 12 In a previous study, we demonstrated that SHRSP5/ Dmcr rats fed an HFC diet developed lipid deposits in the mesenteric arteries, cardiac fibrosis, endothelial dysfunction and LV diastolic dysfunction. 13 However, these rats did not develop occlusions of the coronary arteries or ischaemic heart disease. Ikeda et al. administered the nitric oxide (NO) synthase inhibitor, N G -nitro-L-arginine (L-NNA), to SHRSP/ Izm rats. Although these rats did not develop NASH, these authors were the first to establish the myocardial infarction (MI)-induced hypercholesterolaemic model. 14 Ono et al. reported that SHR rats fed a standard diet and the NO synthase inhibitor, N ω -nitro-L-arginine methyl ester hydrochloride (L-NAME), for 3 weeks experienced apoptosis, coronary arterial remodelling and MI. 15 (NO) synthase synthesis inhibitors affect vascular endothelial function, which promotes lipid deposition in the coronary arteries. We administered L-NAME in a SHRSP5/Dmcr rat model to induce myocardial ischaemia and investigated whether the SHRSP5/Dmcr rats that developed NASH experienced aggravated cardiovascular risk.
| MATERIALS AND METHODS

| Animals and diets
Nine-week-old male rats of the Wistar Kyoto (WKY) (n = 5) and SHRSP5/Dmcr (n = 15) strains were supplied by the Disease Model Cooperative Research Association (Kyoto, Japan). SHRSP5/Dmcr rats are established as parallel lines from outbred WKY rats. 16, 17 In this study, the animals were maintained in a temperature-(24 ± 2°C) and humidity-controlled (55 ± 5%) facility with a 12-hour light/ dark cycle, and were allowed to consume water and an SP diet (20.8% crude protein, 4.8% crude lipid, 3.2% crude fibre, 5.0% crude ash, 8.0% moisture and 58.2% carbohydrate) ad libitum. The HFC diet (a mixture of 68% SP diet, 25% palm oil, 5.0% cholesterol and 2.0% cholic acid) administered to induce NASH was obtained from Funabashi Farm in Chiba, Japan. 1 At 10 weeks of age, the SHRSP5/Dmcr rats were divided equally into 4 groups and fed either an SP or an HFC diet as follows: WKY+SP diet (control (CONT)) group; SHRSP5/Dmcr + HFC diet (NASH) group; SHRSP5/ Dmcr+SP diet+L-NAME (non-NASH+L-NAME) group; and SHRSP5/Dmcr+HFC diet+L-NAME (NASH+L-NAME) group. L-NAME (N-5751, Sigma-Aldrich, Tokyo, Japan) was mixed with drinking water at 16 weeks of age, and the dosage of L-NAME was maintained at 25 mg/kg/day based on the amount of water intake. Body weight, food intake and water intake were measured weekly. Systolic blood pressure (SBP) and heart rate (HR) were measured biweekly in conscious animals using tail-cuff plethysmography (BP-98A; Softron, Tokyo, Japan).
| Ethical approval
All animal experiments were carried out in strict accordance with the recommended standards of the Care 
| Echocardiographic analysis
All rats were anaesthetized intraperitoneally with ketamine (50 mg/kg) and xylazine (10 mg/kg). M-mode LV echocardiograms (ECHOs) with Doppler mitral flow were measured at 18 weeks of age. The ECHO examinations were performed with a 12-MHz transducer (Xario PLT-1202S, SSA-680A; Toshiba Medical Systems, Tochigi, Japan). Anterior and posterior wall thicknesses and LV internal dimensions were measured at end-diastole and end-systole according to a modification of the American Society for Echocardiography leading-edge method of obtaining at least 3 consecutive cardiac cycles for M-mode tracings. [18] [19] [20] [21] The basic parameters for the LV ECHO, LV end-diastolic (LVDd) and end-systolic (LVDs) dimensions, and thicknesses of the interventricular septum (IVST) and LV posterior wall (LVPWT) were measured. LV systolic function was evaluated with respect to LV fractional shortening (%FS), LV ejection fraction (EF) and isovolumic contraction time (ICT). LVEF was calculated according to the formula of Teichholz. HRs were recorded during the ECHOs. LV diastolic function measurements were based on the isovolumic relaxation time (IRT) and deceleration time (DcT). The total ejection isovolumic index (TEI index), which incorporates both systolic and diastolic time intervals to express global systolic and diastolic ventricular function, was calculated as follows: TEI index = (ICT + IRT)/ejection time. 
| Dissection and blood analysis
At 18 weeks of age, blood was collected from the right carotid artery of rats that had been deprived of food overnight. The rats were then anaesthetized by administering an intraperitoneal injection of pentobarbital sodium (50 mg/kg). The blood was centrifuged at 1400 g for 10 minutes at 4°C, and the resultant serum supernatants were maintained at −80°C until analysis. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, triglycerides, lactate dehydrogenase (LDH), creatine kinase (CK) and cardiac troponin T were measured using routine laboratory methods (SRL Inc., Tokyo, Japan). All rats were sacrificed at the time that the blood was drawn, and then, the heart, liver and aorta were removed and weighed. Each rat's body weight (BW) was used to correct its organ weights. The mesenteric artery was separated from the mesenteric adipose tissue for oil red O staining. 23 The hearts and livers were sectioned for histopathological staining, and the aorta was cut into 2-mm rings to evaluate the endothelial function and oil red O staining.
| Histopathological and oil red O staining
The LV and liver were fixed in 10% formalin for 48 hours, embedded in paraffin and sectioned for histology. Transverse sections (5 μm) were stained with standard haematoxylin and eosin (HE). The LV and liver were stained with picrosirius red (PSR) and Masson's trichrome to evaluate fibrosis. Coronary occlusions with thrombus formation and fibrin deposits were evaluated using Elastica van Gieson (EVG) and phosphotungstic acid haematoxylin (PTAH) stains. All images were observed under an all-in-one fluorescence microscope (BZ-X700; KEYENCE, Osaka, Japan). The areas of fibrosis were analysed using ImageJ digital software (NIH, ver. 1.47).
Interstitial fibrosis was evaluated after PSR staining. The areas of fibrosis (stained red) and myocardial fibres (stained yellow) were automatically separated due to the chromatic thresholds. The total area of interstitial fibrosis, including the areas of perivascular fibrosis in the whole LV, was calculated. The dimensions of interstitial fibrosis were corrected using the dimensions of the LV myocardium. Coronary smooth muscle cell (SMC) hypertrophy was evaluated relative to the dimensions of the intravascular lumen. Three coronary arteries in the whole LV were randomly selected, and the averaged dimension of the SMC and intravascular lumen was calculated by tracing these areas using ImageJ digital software.
To evaluate myocardial ischaemia-related cells from the immune system, we immunostained the myofibroblasts, macrophages, T cells, T-helper cells, cytotoxic T cells and B cells using paraffin-embedded sections (4 μm) of antibodies of α-smooth muscle actin (α-SMA) (clone 1A4, Thermo Fisher Scientific, Tokyo, Japan), CD68 (clone ED1, BIO-RAD, Hercules, CA), CD3 (550295, BD Biosciences, NJ), CD4 (19068-1-AP, Protein Group Inc., IL), CD8 (HM3003; Hycult Biotech, PA) and CD20 (sc-393894, Santa Cruz Biotechnology Inc., Heidelberg, Germany) respectively. Endogenous peroxidase activity was blocked by exposing the sections to methanol containing 0.3% H 2 O 2 . Sections were first incubated at 4°C overnight with each antibody and then for 30 minutes with Histofine Simple Stain Rat MAX PO (Nichirei Biosciences, Tokyo Japan). 22 The process for the oil red O staining of the mesenteric artery and aorta was based on previous reports. 23, 24 The mesenteric artery was carefully isolated from the intestine. The aorta and isolated mesenteric artery were fixed in 10% formalin for 10 minutes. After washing with distilled water, the tissue was immersed in 50% isopropanol for 5 minutes, then in oil red O stain solution (O0625; Sigma-Aldrich, Tokyo, Japan) for 10 minutes and then again in 50% isopropanol for 8 minutes.
| Endothelial function
The endothelial function of each rat's aorta was measured at the end of the experimental period. The assay was performed according to the method of Hosoo et al. 25 The rings to obtain concentration-response curves. The vasorelaxation effect was expressed as the percentage relaxation of the PGF2α-induced constriction. After completing the evaluation of endothelial function using ACh, the rings were completely dilated by adding excess vasorelaxant (100 μmol/L papaverine) to confirm that the mesothelium functioned properly.
| Statistical analysis
The relevant data are presented as means ± standard error (SE). Differences among the four groups at 18 weeks of age were assessed using one-way factorial analysis of variance (ANOVA). If a significant difference was detected, intergroup comparisons were performed using Fisher's multiple comparison test. P values < 0.05 were considered statistically significant.
| RESULTS
| Physiological data
As previously reported, 13 SHRSP5/Dmcr rats in the NASH, non-NASH+L-NAME and NASH+L-NAME groups were significantly smaller in size than the WKY rats in the CONT group at 9 weeks of age ( Figure 1A ). The BWs gradually increased in all groups until 16 weeks of age. However, at 17 weeks of age, after L-NAME was administered, the BW of the rats in the NASH+L-NAME group decreased more severely. The SBPs ( Figure 1B ) in the NASH, non-NASH+L-NAME F I G U R E 1 A, Changes in body weight (BW) and B, systolic blood pressure (SBP) at 9-17 weeks of age. Four groups were evaluated: the control (CONT) group comprising WKY rats fed a spoke-prone (SP) diet; the NASH group comprising SHRSP5/Dmcr rats fed a high-fat and high-cholesterol (HFC) diet; the non-NASH+L-NAME group comprising SHRSP5/Dmcr rats fed an SP diet and injected with N ω -nitro-L-arginine methyl ester hydrochloride (L-NAME) at 25 mg/kg/day for 2 weeks; and the NASH+L-NAME group comprising SHRSP5/Dmcr rats fed an HFC diet and injected with L-NAME at 25 mg/kg/day. Data are presented as means ± standard error (SE); n = 5 in each group. *P < 0.05 vs. the CONT group, † P < 0.05 vs. the NASH group, ‡ P < 0.05 vs. the non-NASH+L-NAME group 
BW (g)
Age (wk)
CONT NASH non-NASH+L-NAME NASH+L-NAME and NASH+L-NAME groups were constantly high (over 170 mmHg) between 9 and 17 weeks of age. In particular, the NASH and NASH+L-NAME groups exhibited significantly low level of SBPs as compared to non-NASH+L-NAME until 15 weeks of age (NASH: 178.3 ± 2.7 mmHg, non-NASH+L-NAME: 193.5 ± 4.4 mmHg, NASH+L-NAME: 177.8 ± 4.7 mmHg; p < 0.05). L-NAME increased SBP only in the NASH+L-NAME group at 17 weeks of age. The survival rates of the rats in the CONT, NASH and non-NASH+L-NAME groups during the experimental period were 100% (CONT: n = 5/5, NASH: n = 5/5, non-NASH+L-NAME: n = 5/5). In contrast, survival among the rats in the NASH+L-NAME group was 62.5% (n = 5/8). Dead animals were excluded from the analysis.
| Pathological condition of the liver
Macroscopic liver findings ( Figure 2A) were obviously different in the NASH and NASH+L-NAME groups. The colour tone of the organs among the rats that were fed the HFC diet (NASH and NASH+L-NAME groups) was whiter than that of the other 2 groups, and the liver weights were significantly greater than in those that were fed the SP diet ( Figure 2E ). In addition, the NASH and NASH+L-NAME groups demonstrated severe fibrosis and hepatic steatosis at 18 weeks of age ( Figure 2B ), and their hepatic functions, indicated by AST or ALT, were worse than those of the other 2 groups (Figure 2C,D) . A magnified image of Masson's trichrome staining in the NASH group is shown in Figure S1 . Macrovesicular steatosis (white arrow), ballooned hepatocytes with a Mallory-Denk body formation in some (black arrow), and multilobular necrosis and fibrosis (stained blue) were confirmed. All of these findings are consistent with NASH; however, L-NAME injections had no influence on hepatic fibrosis and function. In contrast, rats in the non-NASH+L-NAME group showed no significant differences compared with those in the CONT group.
| LV fibrosis related to myocardial ischaemia
SHRSP5/Dmcr rats in the NASH, non-NASH+L-NAME and NASH+L-NAME groups had congenital hypertension
F I G U R E 3 Evaluation of left ventricle (LV) hypertrophy in the 4 groups at 18 weeks of age. A-E, Each organ weight is corrected
according to its BW in the A, heart, B, atrium, C, ventricle, D, right ventricle (RV) and E, LV. F, Haematoxylin and eosin (HE) staining of LV myocardium cross sections. The area of myocardial fibrosis is selected in the NASH+L-NAME group. Scale bars = 100 μm. Data are presented as means ± standard error (SE); n = 5 in each group. *P < 0.05 vs. the CONT group, † P < 0.05 vs. the NASH group, ‡ P < 0.05 vs. the non-NASH+L-NAME group [Colour figure can be viewed at wileyonlinelibrary.com] 
RV weight/BW
CONT Non-NASH +L-NAME NASH +L-NAME NASH CONT Non-NASH +L-NAME NASH +L-NAME NASH CONT Non-NASH +L-NAME NASH +L-NAME NASH ( Figure 1B ), which induced a compensated cardiac hypertrophy. 13 The heart, ventricle and LV weights corrected for BW increased significantly more than those in the CONT group ( Figure 3A-E) . NASH+L-NAME group decreased the heart and LV weights compared with the same in the non-NASH+L-NAME group ( Figure 3A ,E). Right heart strain represented by alterations in the atrium or RV weights showed no significant differences among the 4 groups ( Figure 3B,D) . Figure 3F shows the LV section stained by HE, which was selected from Figure 4A section containing fibrosis. Multiple nucleated cells were aggregated in the interstitial region of the LV myocardium in the NASH+L-NAME group only.
In the whole image of the LV sections of the rats in the NASH+L-NAME group, the fibrosis area was remarkably increased ( Figuer 4A) . Almost all infarcted regions were in the subendocardial myocardium (NASH+L-NAME group: n = 4/5). Interstitial fibrosis corrected by the total LV dimension was significantly increased in the NASH+L-NAME group ( Figure 4F ). The NASH and non-NASH+L-NAME groups showed minimal myocardial fibrosis compared to the CONT group. The sections from the NASH+L-NAME group reveal the replacement fibrosis caused by shedding of the cardiomyocytes, which is one of the characteristics in MI ( Figure 4B ). In fact, biochemical markers related to MI, such as LDH, CK and cardiac troponin T, were all increased in the NASH+L-NAME rats ( Figure 4C-E) . In addition, SMCs in the coronary arteries developed hypertrophy in an asymmetric fashion in the NASH+L-NAME group only ( Figure 4B ). The SMC region corrected according to the dimension of the intravascular lumen was the most hypertrophied of all the regions in the NASH+L-NAME group ( Figure 4G) . Furthermore, the NASH+L-NAME group demonstrated thickening and occlusion of the coronary arteries adjacent to the fibrotic areas ( Figure 5 ). The arterial lumens were narrowed by intimal cell proliferation and occluded from thrombus formation ( Figure 5A : EVG staining). Fibrin deposits were observed in the thickened intima and nearly occluded the small lumens ( Figure 5B : PTAH staining). In the NASH (n = 5/5) group and non-NASH+L-NAME group (n = 4/5), there was no evidence to support the occurrence of MI. However, only one sample demonstrated MI similar to that in the NASH+L-NAME group. To investigate the nucleated cells aggregating in the fibrotic region of the NASH+L-NAME group (Figure 3F ), immunostaining for α-SMA, CD68, CD3, CD4, CD8 and CD20 was performed ( Figure 6 ). The α-SMA (myofibroblast) and CD68 (macrophage) were strongly stained in the fibrotic areas. The CD3 (T cells), CD4 (T-helper cells), CD8 (cytotoxic T cells) and CD20 (B cells) cells were all absent in the fibrotic area. These results indicate that the cells in the NASH+L-NAME group developed replacement fibrosis caused by shedding of the cardiomyocytes.
| LV systolic and diastolic function
LV systolic function evaluated by %FS and LVEF was significantly decreased in the NASH+L-NAME group (Table 1) . LV asynergy caused by myocardial necrosis was also confirmed in the M-mode LV ECHO (Figure 7 and Movie S1). The average value of ICT in the NASH+L-NAME group was also extended. LV diastolic function evaluated by DcT was significantly worsened in the NASH+L-NAME group compared to that in the CONT, NASH and non-NASH+L-NAME groups. The IRT and TEI indices were almost equal between the non-NASH+L-NAME and NASH+L-NAME groups.
| Mesenteric and aortic lipid deposition and endothelial function
Many lipid deposits were observed in the mesenteric artery and aorta, only in the NASH+L-NAME group ( Figure 8A,B) . The NASH and non-NASH+L-NAME groups had minimal lipid All data are presented as means ± SE; n = 5 in each group. *P < 0.05 vs. the CONT group, † P < 0.05 vs. the NASH group, ‡ P < 0.05 vs. the non-NASH+L-NAME group. CONT, control group; NASH, non-alcoholic steatohepatitis; L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride; LV, left ventricle; ms, millisecond; SE, standard error.
F I G U R E 7 Echocardiography in the
M-mode on LV echograms in the 4 groups at 18 weeks of age. The non-NASH+L-NAME group represents severe LV hypertrophy, and the NASH+L-NAME group represents depressed LV contractile function deposition, which was obviously less than that in the NASH+L-NAME group. The CONT group had no lipid deposition at all. L-NAME, which induces NO synthase inhibition, interferes with vasodilatation via Ach. 15 The endothelial function in the non-NASH+L-NAME group was significantly impaired after L-NAME injections, and the percentage of maximum contraction was only 60%, even at the 10 −3.5 mol/L ACh concentration ( Figure 9 ). The CONT group exhibited normal endothelial function. The NASH+L-NAME group showed no vascular relaxation at all compared to the non-NASH+L-NAME group. This difference may be due to vascular endothelial dysfunction caused by NASH pathology.
| Lipid metabolism
The rats in the NASH and NASH+L-NAME groups that were fed the HFC diets developed remarkably increased LDL-cholesterol levels and LDL-/HDL-cholesterol ratios (Table 2) . However, HDL-cholesterol and triglyceride were not significantly different among the 4 groups.
| DISCUSSION
The SHRSP5/Dmcr rats with congenital hypertension developed NASH, lipid deposits in the mesenteric artery and hyperlipidaemia as a result of being fed the HFC diets. 1, 26 In addition, we previously reported that SHRSP5/Dmcr rats that were fed the HFC diets developed cardiac and vascular conditions, such as cardiac fibrosis, endothelial dysfunction and LV diastolic dysfunction. 13 However, the important targets in arteriosclerosis research, the aorta and coronary arteries, showed no lipid deposits at all. To overcome this problem, we administered L-NAME to SHRSP5/Dmcr rats fed the HFC diets. The NASH+L-NAME rat group exhibited the following characteristics related to arteriosclerosis and myocardial ischaemia: (a) LV systolic dysfunction and asynergy, (b) replacement fibrosis caused by shedding of the cardiomyocytes and (c) coronary occlusion with SMC hypertrophy and arterial lipid deposits caused by endothelial dysfunction. It is interesting to note that these characteristics were not observed in the NASH or non-NASH+L-NAME groups. These findings demonstrate that NASH aggravates cardiovascular risks in SHRSP5/Dmcr rats.
| SHRSP5/Dmcr as a cardiovascular arteriosclerosis model
Arteriosclerosis is still a critical issue in vascular disease, and the search is ongoing for suitable and desirable arteriosclerosis models similar to human pathology. However, most experimental rodents used for arteriosclerotic research are transgenic models, such as apolipoprotein-E or LDL receptor knockout mice. 23, 27 SHRSP5/Dmcr fed the HFC diets originally developed arterial lipid deposits in the mesenteric arteries without genetic modification. In fact, Yamori et al. first reported that the SHRSP rat, which is the progenitor of the SHRSP5/Dmcr, developed "ring-like" lipid deposits in the mesenteric arteries and cerebral blood vessels. 28 Kunimasa et al. bred a novel SHRSP strain, the SHRSP.ZLepr fa ⁄ IzmDmcr rat (SHRSP fatty), and more severe arterial lipid deposition occurred within a relatively short period of time compared to the SHRSP rat. 23 However, the model of SHRSP fatty rats that developed metabolic syndrome did not clarify the process of lipid deposition in other large arteries, such as the aorta and the carotids. One of the reasons for arteriosclerotic resistance in rodents is strong endothelial function. 14 Ikeda et al. first succeeded in developing MI by administering L-NNA and 1% NaCl to SHRSP rats fed the HFC diets. 14 The salt-induced SHRSP rats developed severe high blood pressures (over 200 mmHg), and the L-NNA injections further aggravated the blood pressure elevations (over 240 mmHg). As a result, the coronary arteries became hypertrophic, thus inducing severe myocardial fibrosis. Our SHRSP5/Dmcr rats fed the HFC and L-NAME also developed hypertrophic coronary arteries ( Figure 4B ,G) and severe myocardial fibrosis ( Figure 4A ,B,F). The histopathological findings were largely similar to those in the SHRSP+L-NNA study. It is unknown whether the SHRSP+L-NNA+1%NaCl group or our SHRSP5/Dmcr+L-NAME group developed more severe MI. The SHRSP+L-NNA+1%NaCl group obviously developed higher blood pressures than our SHRSP5+L-NAME group, but they did not have NASH pathology. The dose and duration of NO synthase inhibitor administration were the same in both studies. We found that the NASH+L-NAME rats developed systolic dysfunction caused by myocardial ischaemia, which is a new finding that was not reported in the SHRSP+L-NNA+1%NaCl study. The rate of LV fibrosis in the SHRSP+L-NNA+1%NaCl group was approximately 4%, 14 whereas that in NASH+L-NAME group was 9.70 ± 1.0%. Ono et al. reported that apoptosis, coronary arterial remodelling and MI were induced in SHR rats fed the standard diets and L-NAME (14.3 ± 0.7 mg/kg/ day) for 3 weeks. 15 The epicardial coronary arteries in the SHR+L-NAME group developed wall-thickening, hypertrophic SMCs and perivascular fibrosis compared to those in the CONT group. However, occlusions of intravascular lumens were not noted in their report. Our SHRSP5/ Dmcr NASH+L-NAME group also developed significantly thickened epicardial coronary arterial walls ( Figure 4B ). Furthermore, coronary occlusions with formation of thrombi and fibrin deposits were observed in the NASH+L-NAME group ( Figure 5 ). The NASH and non-NASH+L-NAME groups developed hypertension ( Figure 1B ) and vascular endothelial dysfunction (Figure 9 ), but did not develop MI. The SHR+L-NAME group 15 had high mean arterial pressures All data are presented as means ± SE; n = 5 in each group. *P < 0.05 vs. the CONT group, † P < 0.05 vs. the NASH group, ‡ P < 0.05 vs. the non-NASH+L-NAME group. HDL, high-density lipoprotein, LDL, low-density lipoprotein; CONT, control group; NASH, non-alcoholic steatohepatitis; L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride; SE, standard error.
(over 220 mmHg), and the increased hypertension might have promoted the coronary injuries. Watanabe heritable hyperlipidaemic (WHHL) rabbits present a suitable MI model of a congenic strain that has pathology similar to that of humans. 29 Hyperlipidaemia in WHHL rabbits is caused by delayed catabolism of LDL in the blood, based on genetic abnormalities of their LDL receptors, which induces arteriosclerosis. 30 WHHL MI rabbits, based on the WHHL strain, spontaneously developed MIs with standard feedings, and they also develop hypercholesteraemia, low HDL levels, insulin resistance and excess visceral fat. 31 SHRSP5/Dmcr rats also had LDL receptor abnormalities that occurred after HFC feedings over 8 weeks. 32 Arterial lipid deposits in SHRSP5/ Dmcr ( Figure 8 ) may be associated with LDL receptormediated hypercholesterolaemia similar to WHHL rabbits. However, it is important to note that the major apoprotein of LDL or very low-density lipoprotein in rats is B48, which is different from that of humans and WHHL rabbits. 33 In research on the breakdown of arteriosclerosis, lipid-rich necrotic cores, infiltration of inflammatory cells and rupture-prone plaques with large lipid cores and thin fibrous caps infiltrated by macrophages are very important. 34 The NASH+L-NAME group did not have ruptureprone plaques ( Figure 5 ), but did have coronary occlusions with formation of thrombi and fibrin deposits, impaired vascular endothelium ( Figure 9 ) and hypertrophic SMCs ( Figure 4G ). Because the fibrotic area in the NASH+L-NAME group was scattered about the subendocardial myocardium ( Figure 4A ), peripheral arterioles must have been occluded. When stenosis of the coronary arteries exceeds 20%, the blood vessel diameters expand towards the exterior (positive remodelling), which is a compensatory reaction to maintain blood flow. 35 Myocardial ischaemia in the subendocardial myocardium was the common denominator between WHHL MI rabbits and our NASH+L-NAME group. High mortality only in NASH+L-NAME group might be caused by myocardial ischaemic aggravation. WHHL MI rabbits show progression of coronary arteriosclerosis over a 24-month period. 31 Although the SHRSP5/ Dmcr rats had small areas of MI, it took only 2 months for them to develop NASH and myocardial ischaemia. Further interventions such as salt loading, administration of a high glycaemic diet and long-term administration of these diets may effectively cause the progression of MI.
| Relationships between NASH and cardiovascular risks in SHRSP5/Dmcr
Patients with NASH exhibit accelerated chronic inflammation in arteriosclerosis, thereby increasing their cardiovascular risk in the presence of progressive non-alcoholic fatty liver disease (NAFLD), more so than patients with simple fatty liver. 9 In the present study, NASH induced-SHRSP5/Dmcr rats fed the HFC diets were administered L-NAME. L-NAME did not aggravate NASH because the non-NASH+L-NAME group did not show any evidence of hepatic fibrosis or liver dysfunction at all (Figure 2 ). In fact, SHRSP5/Dmcr rats fed an HFC diet only (NASH group) demonstrated similar pathological conditions to the rats in the NASH+L-NAME group in this study. The findings that provide evidence of this include the AST, ALT, liver weight/BW and Masson's trichrome-stained histopathological findings (Figure 2 ). Lipid metabolism, as evidenced by HDL-cholesterol, LDLcholesterol and triglyceride levels, was also similar to that of the NASH and NASH+L-NAME groups ( Table 2 ).
The biochemistry results related to the differences in lipid metabolism between the non-NASH+L-NAME group and the NASH+L-NAME group (Table 2) are based on the induction of NASH caused by the HFC diets. The HFC diet markedly increased the LDL-cholesterol levels because it contains 25% palm oil and 5% cholesterol. Hyperlipidaemia is a direct risk factor for arteriosclerosis. Recent reports have suggested that hyperlipidaemia itself aggravates cardiac inflammation, fibrosis, hypertrophy and apoptosis via Toll-like receptor 4 (TLR4) and epidermal growth factor receptors on the myocardium. 36 In our previous study, the NASH group had increased TLR4 mRNA levels compared to those of the WKY rats that were fed an HFC diet (simple fatty liver group) or the SHRSP5/Dmcr rats that were fed an SP diet (non-NASH group). 13 Jia et al. demonstrated that serum interleukin-6 (IL-6) and tumour necrosis factor α (TNF-α) levels in the NASH group were much higher than those in the non-NASH group. 37 It is well known that NASH aggravates systemic oxidative stress and inflammation. 38 In fact, cardiac oxidative stress (RAS-related C3 botulinum toxin substrate 1 mRNA levels) and inflammation (IL-6 or TNF-α mRNA levels) were upregulated in the NASH group. 13 Their results indicate that hyperlipidaemia-induced systemic inflammation caused by NASH aggravates cardiovascular disease. NASH is one of the phenotypes of liver metabolic syndrome. Targher et al. emphasized that insulin resistance is a key factor connecting NASH and cardiovascular disease. 6 It is still unknown whether NASH is associated with cardiovascular disease as a consequence of shared risk factors, or whether NASH contributes to cardiovascular disease independent of these factors. In the former hypothesis, the close correlations between NASH, abdominal obesity and insulin resistance make it extremely difficult to distinguish the precise causal relationships underlying the increased risk of cardiovascular disease among patients with NASH. Recent evidence supports the latter hypothesis, such that activation of the nuclear factor-kappa B pathway in the livers of patients with NASH leads to increased transcription of several proinflammatory genes that amplify systemic, low-grade inflammation. 39, 40 Additionally, circulating levels of several inflammatory markers, procoagulant factors and oxidative stress markers are highest in patients with NASH, intermediate in those with simple steatosis and lowest in control subjects without steatosis. These differences are independent of obesity and other potentially confounding factors. 41 According to previous reports, NASH aggravates arteriosclerosis via insulin resistance and adipocytokines secreted from adipocytes because of obesity. However, lean-type patients with NASH have recently been described clinically. These patients do not have insulin resistance or fat accumulation, and therefore, it is difficult to completely explain the relationship between NASH and cardiovascular diseases based on these intermediary factors. 42 The SHRSP5/Dmcr rat is a lean-type animal with NASH and is not overweight ( Figure 1A ) nor insulin-resistant. 13 In the Greek Atorvastatin Coronaryartery-disease Evaluation trial, atorvastatin significantly decreased cardiovascular disease risk in both lean and obese patients with NAFLD/NASH. [43] [44] [45] This result suggests that hypercholesteraemia may be an intermediary factor between patients with lean-type NASH and cardiovascular disease. We take particular note of bile acids as an alternative intermediary factor. NASH in both humans and SHRSP5/Dmcr rats is associated with increased amounts of bile acids, which are biosynthesized from cholesterol in the liver. 32 Excess bile acids are converted by intestinal bacteria to cytotoxic bile acids, which return to the liver and induce hepatic fibrosis. Simultaneously, cytotoxic bile acids that enter the blood may regulate vascular cell adhesion molecule-1 or intercellular adhesion molecule-1, which are related to intimal-associated macrophage and leucocyte infiltration. 46 
| CONCLUSIONS
We administered L-NAME to SHRSP5/Dmcr rats fed the HFC diets to clarify the relationship between NASH and cardiovascular disease. The rats in the NASH group demonstrated characteristics related to myocardial ischaemia; thus, NASH aggravated cardiovascular risk in the congenic SHRSP5/Dmcr rat model.
